Generation of truncated derivatives through in silico enzymatic digest of peptide GV30 target MRSA both in vitro and in vivo,Computational and Structural Biotechnology Journal

当前位置： X-MOL 学术 › Comput. Struct. Biotechnol. J. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Generation of truncated derivatives through in silico enzymatic digest of peptide GV30 target MRSA both in vitro and in vivo
Computational and Structural Biotechnology Journal ( IF 4.4 ) Pub Date : 2021-08-29 , DOI: 10.1016/j.csbj.2021.08.039
Yingxue Ma ₁ , Aifang Yao ₁ , Xiaoling Chen ₁ , Lei Wang ₁ , Chengbang Ma ₁ , Xinping Xi ₁ , Tianbao Chen ₁ , Chris Shaw ₁ , Mei Zhou ₁

Affiliation

Methicillin-resistant (MRSA) causing serious hospital-acquired infections and skin infections has become a “superbug” in clinical treatment. Although the clinical treatment of MRSA is continuously improving, due to its unceasing global spread, MRSA has produced much heated discussion and focused study, therefore suggesting an urgent task to find new antibacterial drugs to combat this issue. Antimicrobial peptides (AMPs) are used as the last-resort drugs for treating multidrug-resistant bacterial infections, but their utilisation is still limited due to their low stability and often strong toxicity.

中文翻译：

通过体外和体内肽 GV30 靶 MRSA 的计算机酶消化生成截短的衍生物

导致严重医院获得性感染和皮肤感染的耐甲氧西林金黄色葡萄球菌（MRSA）已成为临床治疗中的“超级细菌”。尽管MRSA的临床治疗不断进步，但由于其在全球的不断传播，MRSA引起了广泛的热烈讨论和集中研究，因此寻找新的抗菌药物来解决这一问题刻不容缓。抗菌肽（AMP）被用作治疗多重耐药细菌感染的最后手段，但由于其稳定性低且毒性强，其应用仍然受到限制。

更新日期：2021-08-29

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南11